- Home
- DMO vs IMAB Comparison
DMO vs IMAB Comparison
Compare DMO & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMO
- IMAB
- Stock Information
- Founded
- DMO 2009
- IMAB 2014
- Country
- DMO United States
- IMAB United States
- Employees
- DMO N/A
- IMAB N/A
- Industry
- DMO Trusts Except Educational Religious and Charitable
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- DMO Finance
- IMAB Health Care
- Exchange
- DMO Nasdaq
- IMAB Nasdaq
- Market Cap
- DMO N/A
- IMAB 83.8M
- IPO Year
- DMO N/A
- IMAB 2020
- Fundamental
- Price
- DMO $12.25
- IMAB $1.60
- Analyst Decision
- DMO
- IMAB Strong Buy
- Analyst Count
- DMO 0
- IMAB 3
- Target Price
- DMO N/A
- IMAB $8.00
- AVG Volume (30 Days)
- DMO 49.6K
- IMAB 568.7K
- Earning Date
- DMO 01-01-0001
- IMAB 08-28-2024
- Dividend Yield
- DMO 12.06%
- IMAB N/A
- EPS Growth
- DMO N/A
- IMAB N/A
- EPS
- DMO N/A
- IMAB N/A
- Revenue
- DMO N/A
- IMAB $3,492,091.00
- Revenue This Year
- DMO N/A
- IMAB N/A
- Revenue Next Year
- DMO N/A
- IMAB N/A
- P/E Ratio
- DMO N/A
- IMAB N/A
- Revenue Growth
- DMO N/A
- IMAB N/A
- 52 Week Low
- DMO $10.00
- IMAB $0.99
- 52 Week High
- DMO $11.80
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- DMO 61.72
- IMAB 67.28
- Support Level
- DMO $11.84
- IMAB $1.25
- Resistance Level
- DMO $11.97
- IMAB $1.41
- Average True Range (ATR)
- DMO 0.07
- IMAB 0.13
- MACD
- DMO 0.02
- IMAB 0.02
- Stochastic Oscillator
- DMO 87.80
- IMAB 95.92
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).